Enzyme replacement therapy
Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.
ERT is currently available for some lysosomal storage diseases: Gaucher disease, Fabry disease, MPS I, MPS II (Hunter syndrome), MPS VI and Pompe disease. ERT does not correct the underlying genetic defect, but it increases the concentration of the enzyme that the patient is lacking. ERT has also been used to treat patients with severe combined immunodeficiency (SCID) resulting from an adenosine deaminase deficiency (ADA-SCID).
ERT was developed in 1964 by Christian de Duve and Roscoe Brady. Leading work was done on this subject at the Department of Physiology at the University of Alberta by Mark J. Poznansky and Damyanti Bhardwaj, where a model for enzyme therapy was developed using rats. ERT was not used in clinical practice until 1991, after the FDA gave orphan drug approval for the treatment of Gaucher disease with Alglucerase. ERTs were initially manufactured by isolating the therapeutic enzyme from human placenta. The FDA has now approved ERTs that are derived from other human cells, animal cells (i.e. Chinese hamster ovary cells, or CHO cells), and plant cells.
Lysosomal storage diseases are fatal group of diseases and a main application of ERT. Lysosomes are cellular organelles that are responsible for the metabolism of many different macromolecules and proteins. They use enzymes to break down macromolecules, which are recycled or disposed. As of 2012, there are 50 lysosomal storage diseases, and more are still being discovered. These disorders arise because of genetic mutations that prevent the production of certain enzymes used in the lysosomes. The missing enzyme often leads to a build-up of the substrate within the body. This can result in a variety of symptoms, many of which are severe and can affect the skeleton, brain, skin, heart, and the central nervous system. Increasing the concentration of the missing enzyme within the body has been shown to improve the body's normal cellular metabolic processes and reduce substrate concentration in the body.
ERT has also been successful in treating severe combined immunodeficiency caused by an adenosine deaminase deficiency (ADA-SCID). This is a fatal childhood disease that requires early medical intervention. When the enzyme adenosine deaminase is deficient in the body, the result is a toxic build-up of metabolites that impair lymphocyte development and function. Many ADA deficient children with SCID have been treated with the polyethylene glycol-conjugated adenosine deaminase (PEG-ADA) enzyme. This is a form of ERT that has resulted in healthier, longer lives for patients with ADA-SCID.
|Disease||Enzyme||Administration and Dosage in Pivotal Clinical Trials|
|Fabry disease||Agalsidase beta||IV
Age range 16–61: 1 mg/kg every 2 weeks
|Fabry disease||Agalsidase alfa*||IV
Adult males: 0.2 mg/kg every 2 weeks
Age range 12–69: 15–60 U/kg every 2 weeks
|Gaucher disease||Taliglucerase alfa||IV
Age range 19–74: 11–73 U/kg every 2 weeks
|Gaucher disease||Velaglucerase alfa||IV
Age range 4–62: 15–60 U/kg every 2 weeks
|Gaucher disease type I||Alglucerase||IV
Age range 7–42: 2.5 U/kg 3 times a week, up to 60 U/kg as frequently as once a week or as infrequently as every 4 weeks
|Lysosomal acid lipase deficiency (Wolman disease/CESD)||Sebelipase alpha||IV
Age range 1–6 months: 1 mg/kg every 2 weeks
Age range 4–58: 1–3 mg/kg weekly
Age range 6–43: 100 U/kg weekly
Age range 5–31: 0.5 mg/kg weekly
|MPS IVA||Elosulfase alpha||IV
Age range 5–57: 2 mg/kg weekly
Age range 5–29: 1 mg/kg weekly
|Pompe disease||Alglucosidase alpha (160L bioreactor)||IV
Age range 1–3.5: 20 mg/kg every 2 weeks
|Pompe disease||Alglucosidase alpha (4000L bioreactor)||IV
Age range 10–70: 20 mg/kg every 2 weeks
ERT is not a cure for lysosomal storage diseases, and it requires lifelong IV infusions of the therapeutic enzyme. This procedure is expensive; in the United States, it may cost over $200,000 annually. The distribution of the therapeutic enzyme in the body (biodistribution) after these IV infusions is not uniform. The enzyme in less available to certain areas in the body, like the bones, lungs, brain. For this reason, many symptoms of lysosomal storage diseases remain untreated by ERT, especially neurological symptoms. Additionally, the efficacy of ERT is often reduced due to an unwanted immune response against the enzyme, which prevents metabolic function.
Other treatments for enzyme deficiencies
Substrate reduction therapy is another method for treating lysosomal storage diseases. In this treatment, the accumulated compounds are inhibited from forming in the body of a patient suffering from a lysosomal storage disease. The accumulated compounds are responsible for the symptoms of these disorders, and they form via a multi-step biological pathway. Substrate reduction therapy uses a small molecule to interrupt this multi-step pathway and inhibit the biosynthesis of these compounds. This type of treatment is taken orally. It does not induce an unwanted immune response, and a single type of small molecule could be used to treat many lysosomal storage diseases. Substrate reduction therapy is FDA approved and there is at least one treatment available on the market.
Gene therapy aims to replace a missing protein in the body through the use of vectors, usually viral vectors. In gene therapy, a gene encoding for a certain protein is inserted into a vector. The vector containing the therapeutic gene is then injected into the patient. Once inside the body the vector introduces the therapeutic gene into host cells, and the protein encoded by the newly inserted gene is then produced by the body's own cells. This type of therapy can correct for the missing protein/enzyme in patients with lysosomal storage diseases.
Hematopoietic stem cell (HSC) transplantation is another treatment for lysosomal storage diseases. HSCs are derived from bone-marrow. These cells have the ability to mature into the many cell types that comprise blood, including red blood cells, platelets, and white blood cells. Patients suffering from enzyme deficiencies often undergo HSC transplantations in which HSCs from a healthy donor are injected. This treatment introduces HSCs that regularly produce the deficient enzyme since they have normal metabolic function. This treatment is often used to treat the central nervous system of patients with some lysosomal storage diseases.
- Ries, M (2017). "Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923–2016)". Journal of Inherited Metabolic Disease. 40 (3): 343–356. doi:10.1007/s10545-017-0032-8. PMID 28314976.
- Booth, C; Hershfield, M; Notarangelo, L; Buckley, R; Hoenig, M; Mahlaoui, N; Cavazzana-Calvo, M; Aiuti, A; Gaspar, H. B. (2007). "Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006)". Clinical Immunology. 123 (2): 139–47. doi:10.1016/j.clim.2006.12.009. PMID 17300989.
- Neufeld EF (2006). "Chapter 10: Enzyme replacement therapy – a brief history". In Mehta A, Beck M, Sunder-Plassmann G (eds.). Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis. ISBN 978-1-903539-03-3. PMID 21290685.
- Poznansky, M. J. (1984). "Enzyme-albumin polymers. New approaches to the use of enzymes in medicine". Applied biochemistry and biotechnology. 10: 41–56. doi:10.1007/BF02783734. PMID 6395807.
- Weiss, N (2012). "Cross-talk between TRPML1 channel, lipids and lysosomal storage diseases". Communicative & Integrative Biology. 5 (2): 111–113. doi:10.4161/cib.20373. PMC 3376041. PMID 22808310.
- "Lysosomal Storage Disorders – NORD (National Organization For Rare Disorders)". NORD (National Organization for Rare Disorders). Apr. 2017, from https://rarediseases.org/rare-diseases/lysosomal-storage-disorders/.
- Tartibi, H. M.; Hershfield, M. S.; Bahna, S. L. (2016). "A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient". Pediatrics. 137 (1): e20152169. doi:10.1542/peds.2015-2169. PMID 26684479.
- Coutinho, M. F.; Santos, J. I.; Alves, S (2016). "Less is More: Substrate Reduction Therapy for Lysosomal Storage Disorders". International Journal of Molecular Sciences. 17 (7): 1065. doi:10.3390/ijms17071065. PMC 4964441. PMID 27384562.
- "How does gene therapy work? - Genetics Home Reference." U.S. National Library of Medicine. April 18, 2017, from https://ghr.nlm.nih.gov/primer/therapy/procedures.
- Biffi, A (2016). "Gene therapy for lysosomal storage disorders: A good start". Human Molecular Genetics. 25 (R1): R65–75. doi:10.1093/hmg/ddv457. PMID 26604151.
- Domen, J., Wagers, A., & Weissman, I. "Bone Marrow (Hematopoietic) Stem Cells." April 19, 2017, from https://stemcells.nih.gov/info/Regenerative_Medicine/2006chapter2.htm.
- "GAA: glucosidase alpha, acid". NIH Genetics Home Reference. US Government.